Moderna Announces 94.5% Efficacy of New Coronary Pneumonia Phase III Trial Vaccine

U.S. biotech firm Moderna announced on Nov. 16 that mRNA-1273, a Phase III trial vaccine for neocrown pneumonia developed by the company, was 94.5 percent effective. The plan is to apply for emergency use of the new crown vaccine in the US in the coming weeks, as well as submit the new crown vaccine to other global regulatory bodies for authorization. The company also said it expects to produce between 500 million and 1 billion doses of the neo-crown vaccine globally in 2021.

Just a week ago, a similar vaccine developed by Pfizer and BioNTech SE showed more than 90 percent effectiveness in an interim analysis. Both vaccines rely on mRNA technology, which has never been used to produce an approved vaccine. Soon, the breakthrough will save millions of people around the world from the disease.

Moderna followed up Monday with a statement via Twitter that preliminary analysis of data from more than 30,000 U.S. volunteers showed that Moderna’s vaccine, mRNA-1273, actually prevented all cases of symptomatic Covid-19 caused by the new coronavirus.

According to the report, the analysis evaluated 95 confirmed cases of neo-coronavirus infection in 30,000 subjects, proving the vaccine’s effectiveness at 94.5 percent. The company also stated that no serious safety issues were found and that the vaccine was generally safe and well tolerated. Most of the adverse effects in the subjects were mild or moderate, with side effects mainly including injection site pain, fatigue, muscle pain, and headache.

Moderna reports that its New Crown vaccine has a longer shelf life, with the vaccine remaining stable at refrigerator temperatures for 30 days; it can be stored for up to six months at -20°C. It plans to apply to the U.S. for emergency use of the Neocrown vaccine in the coming weeks, as well as submit the Neocrown vaccine to other global regulatory agencies for authorization.

Moderna expects to produce between 500 million and 1 billion doses of Neocrown vaccine globally in 2021. Moderna was up more than 13% pre-market on the favorable results of these trials.